In addition, levels of type IV collagen ≥ 200 ng/mL (p = 0.011; hazard ratio [HR], 5.300; 95% confidence interval [CI], 1.458–19.270), hyaluronic acid ≥ 143 ng/mL (p = 0.017; HR, 3.922; 95% CI 1.281–12.008), HBsAg ≤ 3.53 log IU/mL (p = 0.027; HR, 5.507; 95% CI 1.220–24.859), sICOS ≥ 164.71 pg/mL (p = 0.022; HR, 3.713; 95% CI 1.210–11.393), sPD-1 ≤ 447.27 pg/mL (p = 0.042; HR, 3.393; 95% CI 1.044–11.033), and sHVEM ≤ 2470.83 pg/mL (p = 0.049; HR, 3.078; 95% CI 1.006–9.416) were significantly associated with HCC development during entecavir treatment (Table 3). Here, HOXD13 is linked to hepatocellular carcinoma.